ArticleInternational journal of general medicine2025
Identification and Validation of a Prognostic Signature Based on mRNAs Associated with Low-Density Lipoprotein Receptor-Related Proteins for Kidney Renal Clear Cell Carcinoma: Insights Into Tumor Immune Microenvironment, Mutation Patterns, and Personalized Treatment Strategies.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-density lipoprotein receptor-related protein (LRP) is integral to protein synthesis and contributes significantly to tumor initiation and growth. However, the role of LRP-related mRNAs (LRPMRs) in KIRC progression remains unclear. Our study investigates the potential use of LRPMRs as prognostic markers in patients with KIRC. Methods: Clinical and transcriptomic data of KIRC patients were obtained from The Cancer Genome Atlas (TCGA) database for model construction and performance evaluation. A nomogram integrating clinical characteristics and the risk model was then established. To explore the clinical significance and underlying mechanisms, we analyzed the tumor microenvironment (TME), evaluated tumor mutational burden (TMB), performed gene set enrichment analysis, and predicted drug sensitivity. The mRNA expression was assessed using RT-qPCR. Results: A six-LRPMR-based model was developed and provided significant prognostic information. Kaplan-Meier analysis demonstrated worse survival outcomes for high-risk (H-R) patients (p < 0.001). A nomogram incorporating the risk model showed improved predictive accuracy compared with the clinical model alone (AUC = 0.761). GSEA highlighted proximal tubule transport and propanoate metabolism pathways as significantly enriched in the low-risk (L-R) group, while the H-R group displayed enrichment in CD22-mediated BCR regulation and FCGR activation pathways. Higher TMB in the H-R cohort predicted a poor prognosis. TME analysis suggested that H-R patients may respond less favorably to immunotherapy. Drug sensitivity analysis indicated that H-R patients were more sensitive to Staurosporine and Sabutoclax, whereas L-R patients were more sensitive to dihydrorotenone and osimertinib. RT-qPCR validated differential mRNA expression between KIRC and normal cells. Conclusion: This six-LRPMR-based prognostic model provides valuable insights for prognosis assessment and personalized treatment selection in KIRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.